Lyra Therapeutics, Inc.
LYRADelisted Apr 20, 2026- Industry
- Surgical & Medical Instruments & Apparatus
- SEC CIK
- 0001327273
Lyra Therapeutics, Inc. was delisted on Apr 20, 2026; its insiders filed their last Form 4 on May 15, 2026; 23 institutions reported holding it in 13F filings for Q4 2025, worth $747.3K in total; no superinvestor held it.
13F holders, Q1 2026
Institutional positions in Lyra Therapeutics, Inc. as of Mar 31, 2026. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
LYRA is no longer listed, and 13F filings after Q4 2025 list far fewer holders. See Q4 2025
- Institutional holders
- 1
- −20 vs. Q4 2025
- Shares held
- 104.1K
- −138.5K (−57.1%) vs. Q4 2025
- Total value
- $51.1K
- −$696.1K (−93.2%) vs. Q4 2025
- New holders
- 0
- 0 more added
- Sold out
- 20
- 1 more reduced
2 institutions that held it in Q4 2025 haven't filed for Q1 2026 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q4 2025: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting LYRA on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 0 | $0 |
| Q1 2026 | 1 | $51.1K |
| Q4 2025 | 23 | $747.3K |
| Q3 2025 | 26 | $2.93M |
| Q2 2025 | 30 | $4.42M |
| Q1 2025 | 57 | $3.23M |
| Q4 2024 | 54 | $5.54M |
| Q3 2024 | 62 | $8.36M |
| Q2 2024 | 51 | $9.06M |
| Q1 2024 | 79 | $283.4M |
| Q4 2023 | 60 | $222.0M |
| Q3 2023 | 45 | $124.8M |
| Q2 2023 | 39 | $138.4M |
| Q1 2023 | 31 | $38.1M |
| Q4 2022 | 37 | $59.9M |
| Q3 2022 | 38 | $96.0M |
| Q2 2022 | 38 | $108.9M |
| Q1 2022 | 28 | $20.2M |
| Q4 2021 | 34 | $22.4M |
| Q3 2021 | 37 | $60.8M |
| Q2 2021 | 46 | $56.0M |
| Q1 2021 | 50 | $87.6M |
Institutions, Q1 2026
Shares, value and share of portfolio for each institution holding Lyra Therapeutics, Inc.; share changes are against Q4 2025.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Sabby Management, LLC | 104,059 | $51.1K | 0.89% | −71,099−40.6% | Reduced |
| Ikarian Capital, LLC | 0 | $0 | 0.00% | −21,161−100.0% | Sold out |
| DRW Securities, LLC | 0 | $0 | 0.00% | −16,812−100.0% | Sold out |
| Geode Capital Management, LLC | 0 | $0 | 0.00% | −12,249−100.0% | Sold out |
| Artia Global Partners LP | 0 | $0 | 0.00% | −8,756−100.0% | Sold out |
| BlackRock, Inc. | 0 | $0 | 0.00% | −2,394−100.0% | Sold out |
| Tower Research Capital LLC (TRC) | 0 | $0 | 0.00% | −2,191−100.0% | Sold out |
| Royal Bank of Canada | 0 | $0 | 0.00% | −1,953−100.0% | Sold out |
| UBS Group AG | 0 | $0 | 0.00% | −675−100.0% | Sold out |
| EverSource Wealth Advisors, LLC | 0 | $0 | 0.00% | −338−100.0% | Sold out |
| Morgan Stanley | 0 | $0 | 0.00% | −334−100.0% | Sold out |
| Jones Financial Companies LLLP | 0 | $0 | 0.00% | −210−100.0% | Sold out |
| Bank of America Corp | 0 | $0 | 0.00% | −201−100.0% | Sold out |
| SBI Securities Co., Ltd. | 0 | $0 | 0.00% | −80−100.0% | Sold out |
| JPMorgan Chase & Co | 0 | $0 | 0.00% | −27−100.0% | Sold out |
| Advisor Group Holdings, Inc. | 0 | $0 | 0.00% | −22−100.0% | Sold out |
| Bryn Mawr Trust Co | 0 | $0 | 0.00% | −20−100.0% | Sold out |
| BNP Paribas Arbitrage, SA | 0 | $0 | 0.00% | −16−100.0% | Sold out |
| Citigroup Inc | 0 | $0 | 0.00% | −3−100.0% | Sold out |
| IFP Advisors, Inc | 0 | $0 | 0.00% | −1−100.0% | Sold out |
| CWM, LLC | 0 | $0 | 0.00% | −1−100.0% | Sold out |
| Comerica Bank | – | – | – | – | Not filed |
| Global Retirement Partners, LLC | – | – | – | – | Not filed |